FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Fulcrum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.70+0.05 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
Fulcrum Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Market Cap | $282.30M | $166.30M |
| Enterprise Value | $233.83M | $87.12M |
| PB Ratio | 0.91 | 2.03 |
| P/TBV Ratio | 0.91 | 2.31 |
Income (trailing twelve months)
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$96.05M | -$21.49M |
| Net Income | -$85.00M | -$22.46M |
| EBITDA | -$96.05M | -$17.14M |
Returns
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -32.4% | -53.2% |
| Return on Assets (ROA) | -30.8% | -41.0% |
| Return on Invested Capital (ROIC) | -35.0% | -32.2% |
| Return on Capital Employed (ROCE) | -30.6% | -38.0% |
Balance sheet
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $48.47M | $62.64M |
| Net Cash (Debt) | $48.47M | $15.77M |
| Net Cash Per Share | $0.64 | $0.66 |
| Equity (Book Value) | $310.70M | $48.61M |
| Book Value Per Share | $4.07 | $1.36 |
| Tangible Book Value | $310.70M | $23.01M |
| Working Capital | $312.55M | $75.09M |
Financial position
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 31.35 | 3.30 |
| Quick Ratio | 4.71 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$65.78M | -$12.39M |
| Capital Expenditures | -$365.00K | -$1.07M |
| Free Cash Flow | -$66.14M | -$20.34M |
| FCF Per Share | -$0.87 | -$0.42 |
Efficiency
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.55M | -$705.27K |
| Employee Count | 55 | 74 |
Dividends and yields
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -30.1% | -22.8% |
| FCF Yield | -23.4% | -9.02% |
| Buyback Yield | -1.50% | -0.73% |
| Shareholder Yield | -1.50% | 0.00% |
Shares
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 76,297,300 | 58,139,000 |
| Shares Change (QoQ) | 14.5% | 0.54% |
| Float | 49,848,400 | 49,154,900 |
| Shares Held by Insiders | 34.7% | 11.6% |
| Shares Held by Institutions | 112.5% | 59.4% |
Scores
| Measure | Fulcrum Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 10.19 | -0.27 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Fulcrum Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.